Real-world GLP-1 adoption, higher doses, orals, discontinuation/muscle/CV risks, and nutrition gaps
Key Questions
How widespread is GLP-1 medication use in the US?
GLP-1 uptake has surged, with 1 in 8 Americans now using these medications. This reflects shifts toward higher protein, produce, and fiber intake alongside their adoption.
What are the latest developments in GLP-1 formulations like Wegovy and oral options?
Wegovy high-dose and oral semaglutide have been approved, along with BrightGene's BGM0504 showing 18-20% weight loss in early data. An oral dual agonist from BrightGene achieved up to 8% weight loss at 8 weeks.
What are the dropout rates and risks associated with GLP-1 medications?
About 50-75% of users discontinue GLP-1 drugs in the first year, with 10-15% lean mass loss and cardiovascular benefits eroding quickly after stopping. Studies show heart health gains from drugs like Ozempic diminish rapidly upon discontinuation.
What nutrition priorities are recommended with GLP-1 use?
Priorities include 20-30g protein per meal, resistance training, fiber, low-carb diets, hydration, and sarcopenia protocols. Cleveland Clinic advises focusing on protein, produce, and fiber while avoiding certain foods on GLP-1 diets.
How can maintenance and adherence be improved with GLP-1s?
Jacksonville's amylin combo shows promise for maintenance. Clinician tools and strategies to combat adherence issues and CV whiplash post-stoppage are key priorities.
Uptake surges (1 in 8 Americans; protein/produce/fiber shifts); Wegovy HD/oral semaglutide/BrightGene BGM0504 approved/early data (18-20% WL); Jacksonville amylin combo for maintenance; 50-75% dropout/yr1, 10-15% lean loss, CV erodes post-stop. Priorities: 20-30g protein/RT/fiber/low-carb/hydration/sarcopenia protocols, clinician tools, adherence/CV whiplash.